Paul S Aisen1, Ronald C Petersen2, Michael Donohue3, Michael W Weiner4. 1. Department of Neurosciences, University of California San Diego, San Diego, CA, USA. Electronic address: paisen@ucsd.edu. 2. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 3. Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA, USA. 4. Departments of Radiology and Biomedical Imaging, Medicine, Psychiatry and Neurology, University of California San Francisco, San Fransisco, CA, USA.
Abstract
INTRODUCTION: This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. METHODS: Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors. RESULTS: The longitudinal data in ADNI-2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical Alzheimer's disease (AD). DISCUSSION: Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient-reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long presymptomatic phase, during which intervention with potentially disease-modifying agents may be most useful.
INTRODUCTION: This article reviews the current status of the Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI), and summarizes planning for the next stage of the project. METHODS: Clinical Core activities and plans were synthesized based on discussions among the Core leaders and external advisors. RESULTS: The longitudinal data in ADNI-2 provide natural history data on a clinical trials population and continue to inform refinement and standardization of assessments, models of trajectories, and clinical trial methods that have been extended into sporadic preclinical Alzheimer's disease (AD). DISCUSSION: Plans for the next phase of the ADNI project include maintaining longitudinal follow-up of the normal and mild cognitive impairment cohorts, augmenting specific clinical cohorts, and incorporating novel computerized cognitive assessments and patient-reported outcomes. A major hypothesis is that AD represents a gradually progressive disease that can be identified precisely in its long presymptomatic phase, during which intervention with potentially disease-modifying agents may be most useful.
Authors: Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski Journal: Lancet Neurol Date: 2013-02 Impact factor: 44.182
Authors: R Scott Mackin; Philip Insel; Paul S Aisen; Yonas E Geda; Michael W Weiner Journal: Int J Geriatr Psychiatry Date: 2011-07-08 Impact factor: 3.485
Authors: M C Donohue; A C Gamst; R G Thomas; R Xu; L Beckett; R C Petersen; M W Weiner; P Aisen Journal: Contemp Clin Trials Date: 2011-04-30 Impact factor: 2.226
Authors: Rebecca E Amariglio; Michael C Donohue; Gad A Marshall; Dorene M Rentz; David P Salmon; Steven H Ferris; Stella Karantzoulis; Paul S Aisen; Reisa A Sperling Journal: JAMA Neurol Date: 2015-04 Impact factor: 18.302
Authors: Ronald C Petersen; Paul Aisen; Bradley F Boeve; Yonas E Geda; Robert J Ivnik; David S Knopman; Michelle Mielke; Vernon S Pankratz; Rosebud Roberts; Walter A Rocca; Stephen Weigand; Michael Weiner; Heather Wiste; Clifford R Jack Journal: Ann Neurol Date: 2013-08 Impact factor: 10.422
Authors: R Scott Mackin; Philip Insel; Duygu Tosun; Susanne G Mueller; Norbert Schuff; Diana Truran-Sacrey; Sky T Raptentsetsang; Jun-Young Lee; Clifford R Jack; Paul S Aisen; Ronald C Petersen; Michael W Weiner Journal: Am J Geriatr Psychiatry Date: 2013-02-06 Impact factor: 4.105
Authors: Michael C Donohue; Reisa A Sperling; David P Salmon; Dorene M Rentz; Rema Raman; Ronald G Thomas; Michael Weiner; Paul S Aisen Journal: JAMA Neurol Date: 2014-08 Impact factor: 18.302
Authors: Reisa A Sperling; Dorene M Rentz; Keith A Johnson; Jason Karlawish; Michael Donohue; David P Salmon; Paul Aisen Journal: Sci Transl Med Date: 2014-03-19 Impact factor: 17.956
Authors: Sebastian Palmqvist; Pontus Tideman; Nicholas Cullen; Henrik Zetterberg; Kaj Blennow; Jeffery L Dage; Erik Stomrud; Shorena Janelidze; Niklas Mattsson-Carlgren; Oskar Hansson Journal: Nat Med Date: 2021-05-24 Impact factor: 53.440
Authors: David A Wolk; Carl Sadowsky; Beth Safirstein; Juha O Rinne; Ranjan Duara; Richard Perry; Marc Agronin; Jose Gamez; Jiong Shi; Adrian Ivanoiu; Lennart Minthon; Zuzana Walker; Steen Hasselbalch; Clive Holmes; Marwan Sabbagh; Marilyn Albert; Adam Fleisher; Paul Loughlin; Eric Triau; Kirk Frey; Peter Høgh; Andrea Bozoki; Roger Bullock; Eric Salmon; Gillian Farrar; Christopher J Buckley; Michelle Zanette; Paul F Sherwin; Andrea Cherubini; Fraser Inglis Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Carey E Gleason; Derek Norton; Eric D Anderson; Michelle Wahoske; Danielle T Washington; Emre Umucu; Rebecca L Koscik; N Maritza Dowling; Sterling C Johnson; Cynthia M Carlsson; Sanjay Asthana Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Javier Oltra-Cucarella; Miriam Sánchez-SanSegundo; Darren M Lipnicki; Perminder S Sachdev; John D Crawford; José A Pérez-Vicente; Luis Cabello-Rodríguez; Rosario Ferrer-Cascales Journal: J Am Geriatr Soc Date: 2018-05-10 Impact factor: 5.562
Authors: Shannon L Risacher; Wesley H Anderson; Arnaud Charil; Peter F Castelluccio; Sergey Shcherbinin; Andrew J Saykin; Adam J Schwarz Journal: Neurology Date: 2017-10-25 Impact factor: 9.910
Authors: Elizabeth C Mormino; Reisa A Sperling; Avram J Holmes; Randy L Buckner; Philip L De Jager; Jordan W Smoller; Mert R Sabuncu Journal: Neurology Date: 2016-07-06 Impact factor: 9.910